Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
13.22 USD | +0.19% | -0.75% | -12.00% |
03/06 | UroGen Pharma Appoints David Lin as New Chief Commercial Officer | CI |
14/05 | Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.00% | 477M | |
+18.95% | 125B | |
+14.17% | 108B | |
-3.49% | 24.57B | |
+3.23% | 22.82B | |
-10.44% | 18.19B | |
-41.48% | 16.54B | |
-12.05% | 16.5B | |
+3.08% | 13.39B | |
+27.98% | 11.1B |
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- Transcript : UroGen Pharma Ltd., Q4 2022 Earnings Call, Mar 16, 2023